CJC-1295 NO DAC

GHRH analogue · Non-acylated · 29 amino acids

Half-life

~30min

After administration

Delivery Method

SubQ injection

Route of administration

Storage (Lyophilised)

12-24 months

room temp (stable)

Storage (Reconstituted)

4–6 weeks

Refrigerate at 2-8C

Known For

Growth hormone releasing hormone (GHRH) analogue. Short half-life (~30 min). Creates GH pulses rather than sustained elevation. Safer than exogenous HGH as it works with the body's natural feedback loop.

Mechanism of Action

Modified GHRH analog (also called Mod GRF 1-29). Signals pituitary to release GH in natural pulsatile pattern. Does NOT flatten GH rhythm.

Body vs. External Supply

🟢 Secretagogue (stimulates natural)

Brand / Trade Names

Mod GRF 1-29 (alternate name) No pharmaceutical brand Research peptide only FDA Category 2 (2023)

Typical Research Dosage

100mcg per injection, 2-3x daily. Must be fasted. Before bed is the priority dose.

Vial Duration Guide

5mg vial at 300mcg/day (3 doses) = ~17 days. 10mg vial = ~33 days.

Recommended Vial Size

★ 5mg vials At 300mcg/day, 5mg = ~17 days ✓. 10mg = 33 days (within 6-week window ✓). 5mg is the sweet spot.

Time to Effects

EARLY: 2-4 weeks FULL: 8-12 weeks Week 1-2: Improved sleep quality (especially with bedtime dose). Vivid dreams are common. Week 2-4: Better recovery, increased energy. Subtle skin improvements. Week 4-8: Fat loss begins, especially around midsection. Improved muscle tone. Week 8-12: Cumulative GH benefits — body composition, skin, recovery all noticeably improved. Much more effective when paired with Ipamorelin. Minimum commitment: 8 weeks.

Contraindications & Do Not Combine

• Do NOT combine with exogenous HGH (HGH suppresses pituitary, making secretagogues pointless) • Do NOT combine with CJC-1295 DAC (same receptor — use one or the other, not both)

Common Side Effects

Flushing (15-20%), headache, dizziness, injection site reaction, possible transient hypoglycaemia

Drug Interactions

Somatostatin analogs (antagonize — cancel effect), glucocorticoids (↓GH response), insulin

Reversibility

🟢 Fully reversible — stimulates natural production. Body returns to baseline within days of stopping.

Key Peer-Reviewed References

All studies are published in indexed journals unless otherwise noted.

• Teichman et al. (2006) J Clin Endocrinol Metab 91:799-805 — Pharmacokinetics in humans • Alba et al. (2006) JCEM 91:1477-82 — GH/IGF-1 response • NOT FDA APPROVED • One death reported in clinical trial (unrelated per investigators) • FDA Category 2 bulk drug substance (2023)

Research Disclaimer

Almost all data is preclinical (animal or in-vitro). No large-scale randomised controlled human trials are available for most compounds on this catalogue. This information is provided for research reference only.

Storage Requirements

Lyophilized: room temp (stable). Reconstituted: 2-8°C, 14-21 days.

State	Condition	Duration
Lyophilised (sealed)	room temp (stable)	12-24 months
Reconstituted	2-8C	4–6 weeks

Reconstitution Note

Reconstitute with bacteriostatic water (BAC water). Do not shake vigorously -- swirl gently to dissolve. Inject BAC water slowly down the side of the vial to avoid denaturing the peptide.

Select Vial Size

$40.00 per vial

Submit Your Test Results →

Quick Reference

Half-life	~30 minutes (short-acting, mimics natural pulse)
Delivery	SubQ injection
Typical dose	100mcg
Storage (lyoph.)	room temp (stable)
Storage (recon.)	4–6 weeks
Endogenous?	Secretagogue (stimulates natural)
Suppression	None (stimulates GH)
WADA	Prohibited (S2)
FDA status	Category 2 (2023)